SCHEMBL720937

SCHEMBL720937

CSc1nnc(-c2ccc(N)cc2)o1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.68
NPC1 O15118 7/20 0.64
RAB9A P51151 7/20 0.64
ALDH1A1 P00352 7/20 0.59
MAPT P10636 4/20 0.59
POLB P06746 2/20 0.59
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
SMN1; SMN2 Q16637 4/20 0.55
KDM4E B2RXH2 4/20 0.55
HSD17B10 Q99714 3/20 0.55
GLA P06280 1/20 0.55
ALOX15 P16050 1/20 0.55
TP53 P04637 2/20 0.54
NFKB1 P19838 1/20 0.54
NFKB2 Q00653 1/20 0.54
RELA Q04206 1/20 0.54
GAA P10253 2/20 0.52
RXFP1 Q9HBX9 2/20 0.50
QPCT Q16769 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL26667254 0.85 CXCR4 (0.61) HPGDNPC1RAB9AALDH1A1MAPT
SCHEMBL20221777 0.83 HPGD (0.70) HPGDNPC1RAB9AALDH1A1MAPT
SCHEMBL20346420 0.82 HPGD (0.64) HPGDNPC1RAB9AALDH1A1MAPT
SCHEMBL20651150 0.81 HPGD (0.58) HPGDNPC1RAB9AALDH1A1MAPT
SCHEMBL6263973 0.81 HPGD (0.68) HPGDNPC1RAB9AALDH1A1MAPT
SCHEMBL8811234 0.81 HPGD (0.68) HPGDNPC1RAB9AALDH1A1MAPT
SCHEMBL408382 0.81 HPGD (1.00) HPGDNPC1RAB9AALDH1A1MAPT
SCHEMBL601473 0.80 NPC1 (1.00) HPGDNPC1RAB9AALDH1A1MAPT
SCHEMBL12897993 0.79 HPGD (0.70) HPGDNPC1RAB9AALDH1A1MAPT
SCHEMBL21336118 0.79 HPGD (0.64) HPGDNPC1RAB9AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3624791-B1 REAGENT FOR SITE-SELECTIVE BIOCONJUGATION OF PROTEINS OR ANTIBODIES UNIV CITY NEW YORK RES FOUND (US) 2026-05-06 EP disclosed
US-20240000964-A1 COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED BY USING THE SAME AJINOMOTO CO., INC. (JP) 2024-01-04 US disclosed
WO-2022154127-A1 COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED THEREFROM 味の素株式会社 2022-07-21 WO disclosed
US-11000604-B2 Reagent for site-selective bioconjugation of proteins or antibodies RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) 2021-05-11 US disclosed
US-11000604-B2 Reagent for site-selective bioconjugation of proteins or antibodies RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) 2021-05-11 US disclosed
US-20200397928-A1 REAGENT FOR SITE-SELECTIVE BIOCONJUGATION OF PROTEINS OR ANTIBODIES RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK 2020-12-24 US disclosed
US-20200397928-A1 REAGENT FOR SITE-SELECTIVE BIOCONJUGATION OF PROTEINS OR ANTIBODIES RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK 2020-12-24 US disclosed
EP-3624791-A1 REAGENT FOR SITE-SELECTIVE BIOCONJUGATION OF PROTEINS OR ANTIBODIES Research Foundation Of The City University Of New York (US) 2020-03-25 EP disclosed
WO-2018213537-A1 REAGENT FOR SITE-SELECTIVE BIOCONJUGATION OF PROTEINS OR ANTIBODIES RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) 2018-11-22 WO disclosed
US-8618145-B2 Small molecular compounds capable of accelerating proliferation of stem cells and use thereof HAN MEI (CN) 2013-12-31 US disclosed
US-20120053214-A1 THE LITTLE MOLECULE COMPOUND WHICH USED FOR PROMOTING THE STEM CELLS HYPERPLASIA AND THE USE THEREOF HAN MEI (CN) 2012-03-01 US disclosed
US-20120053214-A1 THE LITTLE MOLECULE COMPOUND WHICH USED FOR PROMOTING THE STEM CELLS HYPERPLASIA AND THE USE THEREOF HAN MEI (CN) 2012-03-01 US disclosed
US-20120053214-A1 THE LITTLE MOLECULE COMPOUND WHICH USED FOR PROMOTING THE STEM CELLS HYPERPLASIA AND THE USE THEREOF HAN MEI (CN) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240000964-A1 COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED BY USING THE SAME SSB, CTH, SCLY HPGD 3745/4885NPC1 3657/4885RAB9A 331/4885
US-20200397928-A1 REAGENT FOR SITE-SELECTIVE BIOCONJUGATION OF PROTEINS OR ANTIBODIES MRPL21, TFRC, ARGLU1 HPGD 4642/4885NPC1 4336/4885RAB9A 2630/4885
US-11000604-B2 Reagent for site-selective bioconjugation of proteins or antibodies MRPL21, TFRC, ARGLU1 HPGD 4642/4885NPC1 4336/4885RAB9A 2630/4885
US-20120053214-A1 THE LITTLE MOLECULE COMPOUND WHICH USED FOR PROMOTING THE STEM CELLS HYPERPLASIA AND THE USE THEREOF MKI67, KIT, PCNA HPGD 1307/4885NPC1 2926/4885RAB9A 2617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.